Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists

Joana Carvão a Mário Dinis-Ribeiro b, c Pedro Pimentel-Nunes b, d Diogo Libânio b, c

a Gastroenterology Department, Hospital Central do Funchal, Funchal, Portugal; b Gastroenterology Department, Instituto Português de Oncologia do Porto, Porto, Portugal; c MEDCIDS – Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, Portugal; d Surgery and Physiology Department, Faculty of Medicine, University of Porto, Porto, Portugal

Keywords
Neuroendocrine tumors · Gastrointestinal tract · Endoscopy

Abstract
Neuroendocrine tumors (NETs) are rare tumors derived from the neuroendocrine cell system, and more commonly found in the gastrointestinal (GI) tract. Over the last decades, the incidence of GI-NETs has been steadily increasing, partly due to the expanding indications for endoscopy. Most patients with NETs are asymptomatic, and their NETs are noticed during screening examinations; thus, endoscopists are on the frontline of the diagnosis of GI-NETs. Since GI-NETs are less frequent than other malignancies, the natural history, diagnosis, and management of these tumors may not be fully understood. In this review, we aim to update the endoscopist on key clinical features and management of patients with gastric, duodenal, and rectal NETs.

© 2021 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel
Introduction

Neuroendocrine neoplasms (NENs) are rare neoplasms that arise from the neuroendocrine cell system. Previously described as carcinoids, this term is now reserved for metastatic NENs that produce the carcinoid syndrome [1]. Most NENs arise from the gastro-entero-pancreatic tract (GEP-NENs), i.e. from the stomach (23%), appendix (21%), small bowel (15%), and rectum (14%) [2].

GEP-NENs have a global annual age-adjusted incidence rate of 2.39/100,000 inhabitants per year [2]. The incidence is steadily increasing with a 6.4-fold increase from 1973 (1.09/100,000) to 2012 (6.98/100,000), across all sites, stages, and grades [3].

The World Health Organization (WHO) subclassifies NENs of the GI tract and hepatopancreatobiliary organs in order to reflect tumor biology, based on the mitotic count and Ki-67 index (Table 1) [4]. NENs are broadly classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), based on molecular differences – mutations in MEN1, DAXX and ATRX are entity-defining mutations for NETs while TP53 or RB1 mutations define NECs. Genomic data have also led to a change in the classification of mixed NENs. In 2019, the WHO updated its GEP-NEN classification, and a second change concerned the recognition that a small subset of high-grade NETs (G3) are histologically and genetically well differentiated and should no longer be included in the NECs category [4].

Well-differentiated NETs are organized in rosettes, with a trabecular pattern that resembles enterochromaffin cells. In contrast, poorly differentiated NECs are high-grade carcinomas that resemble small cell carcinoma or large cell NEC of the lung [1]. Also, NENs should be staged according to a specific tumor-node-metastasis (TNM) staging, as proposed by the European Neuroendocrine Tumor Society (ENETS) [5]. These classification and staging systems are useful for guiding therapeutic decisions and establishing prognosis.

As previously stated, the incidence of GEP-NENs is steadily increasing, and one contributing factor seems to be the expanding indications of endoscopy. Therefore, endoscopists are in the first line of diagnosis of gastrointestinal tract NETs (GI-NETs), predominantly gastric, duodenal and rectal lesions. When facing a lesion suspicious of a NET, the endoscopist should decide whether to biopsy or remove the lesion (and choose the resection technique), suggest/request adequate diagnostic and staging laboratory, and/or radiological exams. Although several national and international society guidelines have been published regarding the management of GI-NETs, we would like to emphasize that evidence on this topic is still scarce, and thus most of the recommendations are based on expert opinion. With this review, the authors aim to provide a practical and focused update on the management of well-differentiated NETs most frequently encountered in routine endoscopy. The management of poorly differentiated NECs and advanced disease is beyond the scope of this article and will not be addressed.

Gastric NETs

Gastric NETs (g-NETs) are the most frequent of all digestive NETs, representing up to 23% of the cases, with an annual age-adjusted incidence of 0.2/100,000 [2, 6]. g-NETs are further subclassified into subtypes based on clinicopathological characteristics, with important therapeutic and prognostic implications (Table 2) [1].

Type I g-NETs represent 70–80% of all g-NETs and are associated with advanced atrophic gastritis with corpus atrophy, more commonly with chronic autoimmune atrophic gastritis [6]. In this setting, compensatory hypergastrinemia induces proliferation of enterochromaffin-like (ECL) cells, hyperplasia, and, ultimately, NET [7]. They are more frequent in females and commonly associated with other autoimmune diseases (vitiligo, type 1 diabetes, Hashimoto’s thyroiditis) [6]. Most type I g-NETs are small (<1 cm), G1 tumors, limited to the mucosa or submucosa (SM) [8]. Lymph node metastasis (LN) are detected in 2–9% of the tumors, particularly if greater than 1–2 cm, with muscularis propria (MP) invasion, or angioinvasion [9].

Type II g-NETs are rare, representing only 5–6% of g-NET cases, and commonly found in patients with Zollinger-Ellison syndrome (ZES) and MEN-1 (multiple endocrine neoplasia syndrome-1), primarily caused by duodenal gastrinomas [8, 10]. The non-compensatory hypergastrinemia induces ECL-cells hyperplasia in the stomach, leading to the development of these tumors. Like type I, they are usually small, well-differentiated tu-
Type III g-NETs are sporadic tumors that account for 15–20% of g-NETs and are more frequently found in men with a median age of 50 years [8]. Most of these tumors are large (>1 cm), infiltrate the MP, show angioinvasion, and present with LNM (50–100%) at the time of the diagnosis [6, 9]. However, it should be stated that with the widespread use of endoscopy, small and low-grade type III g-NETs are being increasingly detected [11].

Type IV g-NENs were included in the classification to harbor the poorly differentiated NECs of the stomach. They are rare, sporadic tumors that typically present in elderly male patients [12]. They are the most aggressive type of g-NENs, and most of the patients have metastatic disease at diagnosis [1].

**Clinical Presentation and Endoscopic Features**

Most g-NETs, particularly in early forms, are incidental findings on endoscopy. Type I patients may present with dyspepsia or might be referred for anemia. Type II

---

**Table 1. 2019 World Health Organization Classification of Neuroendocrine Neoplasms of the gastrointestinal tract and hepatopancreato-biliary organs [4]**

| Terminology                                      | Differentiation | Grade | Mitotic rate*, mitoses/2 mm² | Ki-67 index*, % |
|--------------------------------------------------|-----------------|-------|-----------------------------|----------------|
| NET, G1                                           | Well differentiated | Low   | <2                          | <3             |
| NET, G2                                           | Well differentiated | Intermediate | 2–20                       | 3–20           |
| NET, G3                                           | Well differentiated | High   | >20                         | >20            |
| NEC, small cell type                              | Poorly differentiated | High   | >20                         | >20            |
| NEC, large cell type                              | Poorly differentiated | High   | >20                         | >20            |
| Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) | Well or poorly differentiated | Variable | Variable | Variable |

NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma. * Final grade is based on whichever of the two proliferation indexes places the neoplasm in the higher category.

**Table 2. Characteristics of different subtypes of g-NETS; Common findings are reported**

|                        | Type I          | Type II         | Type III         | Type IV         |
|------------------------|-----------------|-----------------|------------------|-----------------|
| g-NET, %               | 70–80           | ~5              | 15–20            | Rare            |
| Associated conditions  | Chronic autoimmune gastritis | Zollinger-Ellison MEN-1 | Sporadic         | Sporadic         |
| Endoscopy              | Multiple, small (<1 cm) tumors on fundus/body yellow/red color | Single, >1 cm* tumors anywhere in the stomach | Single, large (>2 cm), ulcerated |
| Pathology              | G1/G2 NET       | G3 NET*         | NEC              |
| Serum gastrin          | ↑               | ↑               | Normal           | Normal          |
| Gastric pH             | ↑               | ↓               | Normal           | Normal          |
| Serum chromogranin A   | ↑               | ↑               | Normal           | Normal          |
| Metastases, %          | Very rare       | 5–12            | 30–80            | 80–100          |
| Tumor-related deaths, %| <1%             | <10             | 25–30            | >50             |

NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; MEN-1, Multiple Endocrine Neoplasiasyndrome-1.* Infracentimetric, G1/G2 lesions are being increasingly diagnosed.
patients can present with abdominal pain and diarrhea as part of ZES, while type III/IV patients have a clinical presentation similar to gastric adenocarcinoma. On esophagogastroduodenoscopy (EGD), type I and type II are indistinguishable. They are usually multiple, small (<1–2 cm), yellow or reddish, polypoid, or submucosal lesions (with or without central depression or ulceration) more frequently found in the fundus and corpus [7] (Fig. 1). Abnormally reduced or flattened gastric folds suggest type I, while hypertrophic gastric folds and diffuse gastric and duodenal ulceration suggest type II. Narrow-band imaging (NBI) does not seem to add further information to the optical diagnosis. Indeed, in a recent study of patients with chronic gastritis under surveillance, even though g-NETs showed an abnormal mucosal pattern with NBI, no specific features were able to distinguish them from other intraepithelial lesions [13]. Therefore, biopsies should always be performed to confirm the optical diagnosis. Type III tumors are typically single and large (>1 cm), even though with the widespread practice of endoscopy, they are increasingly diagnosed at early stages and smaller sizes [9, 11] (Fig. 2). Type IV are often ulcerated, large lesions (5–7 cm) indistinguishable from adenocarcinomas [9].

**Diagnosis**

If a g-NET is suspected on EGD, biopsy samples should be taken from the (largest) lesions and also from the antrum (at least two biopsies), body, and fundus (at least four biopsies) to confirm mucosal atrophy and *H. pylori* status [6]. It should also be noted that in the case of a few small lesions (<1 cm), direct polypectomy can be considered.

After histopathology confirmation, further laboratory tests are needed to assess subtype. All require measurement of serum gastrin and chromogranin A (CgA) [14]. Gastrin and CgA measurements should be performed at least 2 weeks after stopping proton pump inhibitors (PPIs), since they may be responsible for false positive results [1]. Assessment of anti-parietal cell and anti-intrinsic factor autoantibodies, as well as vitamin B₁₂ and thyroid panel, also support type I diagnosis. The diagnosis of type II should also rely on clinical and family history and requires additional testing for serum parathyroid hormone and calcium. The diagnosis of type III/IV g-NETs is made when type I/II is excluded (Table 2) [8].

**Staging**

In type I g-NETs <1 cm, EGD is the only recommended procedure. In all g-NETs, if the tumor is ≥1 cm, endoscopic ultrasound (EUS) is recommended to evaluate the depth of invasion, LNM, and appropriateness for endoscopic resection (ER), although there are no large studies assessing EUS diagnostic yield [6, 15]. EUS can also be useful to assess the location of the gastrinoma in type II g-NETs.
Due to the indolent behavior of type I, further staging with computed tomography (CT), magnetic resonance imaging (MRI), and somatostatin receptor positron emission tomography (SSTR-PET) are seldom necessary unless there are signs of MP invasion or LNM on EUS evaluation [10]. In types II and III, further staging with CT/MRI and SSTR-PET is recommended [16, 17]. SSTR-PET is superior to both conventional imaging and SSTR scintigraphy for initial staging [17].

**Management/Follow-Up/Prognosis**

Treatment options depend on tumor type, size, and staging.

**Type I**

The prognosis of type I is excellent, with 5-year disease-specific survival higher than 95%. Recommendations vary slightly across European and North American Neuroendocrine Societies (ENETS and NANETS, respectively) (Table 2) [6, 16, 18]. According to both guidelines, tumors < 1 cm should be offered surveillance and not ER, although a more aggressive approach with ER of all visible lesions (biopsy forceps/snare polypectomy for < 5 mm and endoscopic mucosal resection, EMR, > 5 mm) or ER of only larger lesions is also considered as an option in both guidelines [16, 18]. In larger lesions, recommendations differ between guidelines. ENETS recommends ER of all lesions ≥ 1 cm (without MP invasion), while NANETS recommends resection of lesions > 2 cm but still consider endoscopic surveillance every 3 years as an option in lesions 1–2 cm without SM invasion (although resection should be preferred in case of SM invasion) [16, 18]. If we acknowledge the fact that the risk of metastatic disease has been associated with tumor size (cut off ≥ 1 cm), ENETS’s approach seems more reasonable [19].

ER consists of EMR or endoscopic submucosal dissection (ESD), preferably by experienced endoscopists [18]. There are only a few case reports of device-assisted EMR for g-NETs published in the literature, with the largest studies concerning conventional EMR. There are also no large studies comparing conventional EMR and ESD. Only one small retrospective study has compared EMR and ESD in type I g-NETs but was restricted to < 1 cm lesions [20]. In this study including 87 lesions, EMR achieved a higher but not statistically significant, complete pathological resection (CPR) rate (95 vs. 83%, p = 0.17) but at the cost of a higher but also non-significant complication rate (15 vs. 6%, p = 0.28 immediate bleeding, 3 vs. 0%, p = 0.44 perforation) and increased procedural time (26.1 ± 10.5 vs. 9.5 ± 3.6 min, p < 0.001) [20]. However, the goal of CPR rates in well-differentiated lesions may not even be significant regarding long-term outcomes. Indeed, Jung et al. [21] found no tumor recurrence during the follow-up (FU) in patients with NET G1/G2, even in patients with positive margins after ER (EMR or ESD). In fact, Uygun et al. [22] have reported 100% survival and disease-free rates during a median FU of 7 years after EMR of small, type I g-NETs. Therefore, for < 1 cm tumors, EMR may be a better therapeutic approach.

In our practice, after proper staging, we favor the following management (Fig. 3): for one or two ≤ 5-mm lesions, ER with biopsy forceps or cold snare polypectomy instead of surveillance only since the risk of ER is very low and most of the times it is complete; for multiple ≤ 5-mm lesions, we favor annual endoscopic surveillance (considering ER of NETs that show some irregular features); for 5- to 15-mm lesions, we prefer EMR over ESD since in most of these cases complete resection is possible and the clinical value of positive margins is not clearly determined; for > 15-mm lesions, depressed morphology (IIC lesion), or atypical features, we tend to choose ESD to enable complete resection and proper histological staging.

Surgery should be limited to cases with invasion beyond SM, LNM, and G3 lesions [6]. Somatostatin analogs (SSAs) and netazepide may reduce tumor burden and progression, and they have been used to treat patients with multiple small lesions, although their role is not perfectly established [18].

Type I g-NETs are recurring tumors due to persistent antral-mediated hypergastrinemia [23]. Regardless of resection, ENETS propose routine assessment of CgA, gastrin, iron, and vitamin B12 every 6–12 months and EGD every 12–24 months [24] (Table 3). At any surveillance, biopsies of new lesions should be performed [6].

**Type II**

Management is mainly influenced by the presence of concomitant duodenal or pancreatic NETs as part of the MEN-1 syndrome and requires a multidisciplinary decision. If indicated, according to ENETS, all lesions should be resected even in the presence of multiple lesions [6]. ER is indicated for all localized lesions and surgery for those with invasive or metastatic disease. NANETS, however, offers the possibility of surveillance in lesions smaller than 1 cm [16]. In addition, the resection of the co-existing gastrinomas should be attempted [8]. High-dose PPIs is recommended to suppress acid secretion and symptom relief in ZES.

The prognosis is good, with an associated mortality of less than 10% [6]. FU is identical to type I, with the excep-
Table 3. Summary of recommendations regarding follow-up according to ENETs [24]

| Location          | FU interval | CgA | Markers                        | Endoscopy         | CT/MRI/PET                      | Comments                                                                 |
|-------------------|-------------|-----|--------------------------------|-------------------|---------------------------------|--------------------------------------------------------------------------|
| **Gastric**       |             |     |                                |                   |                                 |                                                                          |
| Type I            | Resected or primary surveillance strategy | 6–12 m | Every visit | Gastrin, iron, vitamin B12 every visit | EGD every 12–24 m | Not recommended | EUS not routinely recommended, may be useful if progression or recurrence is suspected |
| Type II           | Resected or primary surveillance strategy | 6–12 m | Every visit | Gastrin, serum calcium, PTH every visit | EGD every 12–24 m | CT/MRI recommended every visit SSTR-PET every 12–24 m* |                                                                          |
| Type III          | Resected    | 2–3 m | Every visit | Not routinely recommended | EGD every 6–12 m | CT/MRI every 2–6 m SSTR-PET every 12–24 m* |                                                                          |
| **Duodenal**      |             |     |                                |                   |                                 |                                                                          |
| Gastrinoma        | Resected    | 6–12 m | Every visit | Gastrin, serum calcium, PTH every visit | EGD every 12 m | CT/MRI every 12 m SSTR-PET every 12–24 m* | EUS not routinely recommended, may be useful if progression or recurrence is suspected |
| Other type        | Resected    | 3–6 m | Every visit | Relevant tumor hormones | EGD every 12 m | CT/MRI every 6–12 m* SSTR-PET every 12–24 m* |                                                                          |
| **Rectum**        |             |     |                                |                   |                                 |                                                                          |
| <1 cm, G1, R0 and no adverse features | Once | Not recommended | | | | | |
| 1–2 cm, G1, R0 and no adverse features | At least once or every 12 m | Every visit | Not recommended | EUS once Colonoscopy every 6–12 m | CT/MRI at least once or every 3–12 m | |
| >2 cm, G3, R1/2 or any adverse features | 6–12 m | Every visit | Not routinely recommended | Colonoscopy every 6–12 m | CT/MRI every 3–12 m SSTR-PET every 12–24 m* | |
| **NET G3/NEC**    | Resected    | 3/3 m for 2–3 y 6–12/6–12 for 5 y | Every visit | Not routinely recommended | Follow primary tumor location recommendation | CT/MRI every visit FDG-PET may be useful in select patients | |

* Only if positive at diagnosis. CgA, chromogranin A; CT, computed tomography; EGD, esophagogastroduodenoscopy; EUS, endoscopic ultrasound; Fluorodeoxyglucose-positron emission tomography (18FDFG-PET); FU, follow-up; MRI, magnetic resonance imaging; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; SSTR-PET, somatostatin receptor positron emission tomography.
tion that these patients may also benefit from additional CT/MRI every 6–12 months (Table 3) [24].

Our endoscopic management is similar to type I, with the exception that, whenever possible, we prefer ER of all visible tumors instead of surveillance, even for small tumors (Fig. 3).

Type III

The prognosis is poor, with a mortality rate of 25–30% and 5-year survival of 50% or less. Since the majority of patients present with large lesions, MP invasion, LNM, and angioinvasion at diagnosis, guidelines still recommend surgery (partial or total gastrectomy with lymph node dissection) as the preferred approach [6, 16, 18]. However, Kwon et al. [25] have demonstrated that ER can be safely performed in lesions < 20 mm, G1, confined to mucosa/SM, and without lymphovascular invasion. In this study, 50 lesions were submitted to ER (41 by EMR and 9 by ESD) with 80% CPR rate. Incomplete resections due to lymphovascular invasion were submitted to additional surgery, while patients with margin invasion were followed up. During FU (median 44 months), there was no evidence of tumor recurrence or mortality in either the complete resection group or incomplete resection group [25]. ASGE also supports this approach, suggesting ER for isolated type III g-NETs < 1 cm [26]. ENETS propose an intensive FU for type III g-NETs with biochemical and imaging studies every 2–3 months and EGD every 6–12 months (Table 3) [18].

From our experience, after proper staging, we suggest the following management (Fig. 3): for lesions ≤ 1 cm and no evidence of LNM, ER (EMR or ESD) is preferred over surgery (even though this is always discussed with the patient) to allow proper histological staging and eventually curative resection; for lesions between > 1 and ≤ 2 cm and no evidence of MP invasion or LNM, we favor ER by ESD over surgery to allow proper histological staging (except in the young and fit patient where surgery is also first line); for lesions > 2 cm, ER should not be an option and surgical and/or medical treatment should be offered to these patients.

Type IV

Type IV g-NETs have an extremely poor prognosis with a 50% mortality rate at 1 year. ER is not adequate for NEC even in the rare cases of a T1 tumor [9]. If the disease is localized, surgery may be indicated, while in patients with advanced disease, systemic therapy is advised [9].

Overall, after ER of g-NETs, surgical treatment should be considered if lymphovascular invasion, G3 grading, or MP invasion. If positive margins, we typically schedule additional ER in 3–6 months and only consider surgery if recurrence not amenable to further ER or in type III tumors.
Duodenal NETs (d-NETs) are rare, accounting for 2.8% of all NETs with an annual age-adjusted incidence of 0.19/100,000 [27, 28], and are more common after 50 years of age, with a slight male predominance [27]. Duodenal NENs comprise mainly gastrinomas, somatostatinomas, non-functional tumors (that may stain for calcitonin and serotonin), duodenal gangliocytic paragangliomas, and high-grade poorly differentiated NECs [6]. Overall, most of d-NENs are non-functional, well-differentiated, located in the proximal duodenum, and rarely present with local or distant metastasis at diagnosis (less than 10%) [27, 29]. Functional d-NENs (e.g., ZES in gastrinomas) have a high risk of metastatic disease at presentation even if small size and will not be discussed in detail [12].

- **Clinical Presentation and Endoscopic Features**
  The majority of patients are diagnosed incidentally during EGD. Rare presentations include symptoms related to functioning tumors like ZES [6]. On EGD, d-NETs are typically single, small (mean size 1.5 cm), sessile, pale, or reddish lesions found in the duodenal cap or bulb [10]. As the tumor grows, a depression may form in the center, which is eventually replaced by an ulcer crater [31]. To date, there have been no studies concerning the role of NBI to aid in the optical diagnosis.

- **Diagnosis and Staging**
  EGD with biopsy is the most sensitive modality for the diagnosis [6]. EUS with fine needle aspiration should also be performed in cases of non-diagnostic histopathology, for local staging (tumor invasion and LN metastasis) prior to ER, and in patients with MEN-1 with the additional ability to assess the pancreas for pancreatic gastrinomas [15]. CT/MRI and PET-CT are also indicated. If liver metastases are detected, further MRI of the spine and bone scintigraphy should be performed [6].

- **Management**
  Management is based on tumor size, location, histological grade, stage, and tumor type.

- **Ampullary d-NETs**
  Pancreatoduodenectomy has been recommended for resectable ampullary d-NETs regardless of size, due to a relatively high risk of occult LNM [18]. However, these recommendations were based on small case series, and treatment decisions should be individualized based on precise tumor location, histological grade, depth of invasion, and patient suitability for aggressive surgery. In one of the largest studies of ER of d-NETs (only EMR), which included 7 ampullary G1/G2 NETs with ≤20 mm, without MP invasion or LNM, CPR was achieved in 5 patients (71%). On FU, no patient in the CPR group presented recurrence, while 1 patient in the incomplete resection group presented with LNM [32]. The overall complication rate was 34%, with 3% procedure-related death. The majority of complications included intraprocedural bleeding, controlled with further endoscopic treatment [32]. However, if we take into account the significant morbidity and mortality rates of a pancreatoduodenectomy, ER may be a more reasonable alternative in selected patients.

- **Non-Ampullary d-NETs**
  Small (≤1 cm) G1/G2 d-NETs without local or distant metastases are eligible for ER. Several ER methods have been proposed, including ESD, EMR, EMR with ligation devices, hybrid-EMR, underwater submucosal resection, endoscopic full-thickness resection (EFTR), and recently endoscopic banding without resection [33–40].

  In small d-NETs, Kim et al. [33] have reported a CPR rate of 100% (4/4), with no recurrence at a mean FU of 17 months after ER. ESD had a higher rate of minor intra-procedural bleeding (75 vs. 6%), and longer procedure time (average 33 vs. 13 min) when compared to EMR [33]. In two small series by Matsumoto et al. [34] and Suzuki et al. [35], the perforation rate with ESD was exceedingly high (2/5 and 2/3, respectively).

  With EMR and EMR-based techniques (band ligation and circumferential precutting), the procedure time is shorter, with fewer complications and with complete ER rates that range from 89 to 100%. Even though CPR rates were lower, ranging from 25 to 56%, if endoscopic complete resection was achieved and the invasion depth was limited to the SM, recurrence was not observed during the FU assessments [33].
In a recent review of 15 duodenal lesions resected with EFTR, the CPR rate was 93%, with a complication rate of 27% (3 micro-perforations and 1 perforation) [41].

Overall, the majority of these studies are small, non-controlled retrospective case series, case reports with a paucity of data regarding long-term outcomes. Therefore, the ER method should be chosen according to tumor location, shape, size, and, most importantly, endoscopist expertise.

In our practice (even though we have ESD experience), EMR based techniques are preferred whenever possible for small (<1 cm) d-NETs, most of the times allowing a complete and safer resection (Fig. 4).

Large (≥2 cm), G1/G2 d-NETs without metastases should be surgically resected as well as d-NETs of any size with LN metastases [6].

The management (ER vs. surgery) for intermediate size d-NENs (1–2 cm), G1/G2 d-NETs without metastases is still not standardized [18]. Even though most may be endoscopically resected, the risk of LNM is considerable, and a decision should be made on a case-by-case scenario [12].

In these cases, we consider ER only when the location of the tumor may imply a more aggressive surgery and/or when the patient is less fit for surgery (Fig. 4).

G3 tumors and poorly differentiated NEC require oncological surgical resection with adjuvant chemotherapy [6].

For the minority of patients with a functional clinical syndrome (10%), oncological surgical resection if resectable and appropriate specific therapy are indicated (e.g., PPIs in ZES, SSAs in carcinoid syndrome) [6].

**FU and Prognosis**

The prognosis is dependent on size, grade, and functionality. Overall, patients with non-functioning d-NETs have a fare better outcome, and patients with high-grade d-NETs have a worse outcome than adenocarcinoma [42].

Non-functional d-NETs should be followed every 6–12 months with CgA and relevant tumor hormones and yearly EGD and imaging studies (Table 3) [24].

---

### Rectal NETs

Rectal NETs (r-NETs) have an annual age-adjusted incidence of 0.86/100,000 in the United States. r-NETs represent 27% of gastrointestinal NETs overall, with higher rates (>60–80%) being reported in Japanese and South Asian populations [27, 28, 43]. There is a male predominance, and the mean age at diagnosis is 57 years [27].

Most r-NETs arise from L-cells and are characterized by the production of glucagon-like peptide, pancreatic polypeptide, and peptide YY. Most tumors are small (<10 mm) and grade G1/G2 [44, 45]. Local and/or distant metastasis are present at diagnosis in 3, 6, and 73% of tumors measuring ≤10, 11–19, and ≥20 mm, respectively [46].

**Clinical Presentation and Endoscopic Features**

The majority of patients are asymptomatic, and lesions are found during screening colonoscopy [46]. On endoscopy, r-NETs are generally small (<1 cm in 85% of cases), smooth, round, mobile, yellowish submucosal lesions with a reddish tinge, significant microvessel density, sometimes with a central punctum and found between 5–10 cm of the anal verge in 87% of the cases [47]. Atypical findings include a semipedunculated shape (10%), erosion (8%), and ulceration (6%). These atypical forms seem to predict a more aggressive form of disease [47]. In the only case report where r-NET is described under magnifying NBI, it showed small round pits, surrounded by brown, honeycomb-like microvessels [48].

**Diagnosis and Staging**

The majority of r-NETs are diagnosed endoscopically. In some cases, r-NET resemble epithelial polyps, are
removed in index endoscopy, and the diagnosis is only made after histopathological analysis [44]. However, it should be stated that an ER in index colonoscopy should not be pursued if any high-risk stigmata (i.e., atypical features, >10 mm) are present due to the higher risk of invasion and metastases. Therefore, biopsy should be taken for histological confirmation in suspected r-NETs over 5 mm and/or high-risk stigmata, while EMR may be performed in smaller lesions at index colonoscopy [23]. Also, a full colonoscopy is required at some point, as part of staging, and to exclude synchronous carcinoma [44].

EUS is recommended in all lesions >5–10 mm or with atypical features to assess depth of invasion and the presence of LNM [15, 23, 44]. A small study on the use of EUS in 22 rectal NENs showed a 100% accuracy for EUS in assessing invasion depth before ESD [49].

Additional imaging includes a thoracic, abdomen, and pelvic CT in patients with lesions >1 cm and when LNM is suspected invasion depth before ESD [49].

It should also be noted that incomplete resection of r-NETs does not preclude endoscopic salvage resection [23]. Reported salvage therapies include device-assisted EMR, ablation, ESD, and local surgical excision [54–56]. According to ENETS, if EMR leads to incomplete resection, ESD or transanal endoscopic microsurgery (TEMS) may be indicated, without evidence to support one over another [45]. Recent techniques such as EFTR also play a role as salvage therapy or even as primary ER in r-NETs with 10–20 mm or G2 grading, as was recently demonstrated by Meier et al. [57].

TEMS may also be considered as a primary resection method for r-NETs 1–2 cm, G1-G2, confined to the SM or small-sized r-NETs (<1 cm), G2-G3, with MP invasion but without LNM [44]. Rectal tumors >2 cm, between 1–2 cm with MP invasion, T3-T4 stage, G3 grading, or lymph node involvement should be treated with rectal anterior resection or abdominoperineal resection if in the lower rectum [44].

From our experience, most r-NET ≤5–7 mm can be safely and completely removed by standard EMR. For tumors 8–10 mm, we prefer device-assisted EMR or ESD/EFTR if the tumor presents depressed morphology (0–IIc). However, for tumors 10–15 mm, surgery is always discussed with the patient, but if staging procedures exclude MP involvement and LNM, we prefer ESD or EFTR over EMR to allow safer margins and proper histological diagnosis. For tumors 15–20 mm, even when staging procedures do not show LNM, surgery is our preferred approach since the risk of microscopic LNM is substantial in these cases. If the patient refuses or is less fit for surgery, we prefer ESD or TEMS over other methods. In the com-
mon scenario of a patient with a previously resected <10-mm polyp that showed to be a G1/G2 NET with positive margins (without other risk features), we repeat endoscopy at 3 months. If the scar does not show macroscopic recurrence/residual tumor, we always perform biopsies, and if the scar shows residual tumor, we prefer EMR based techniques or ESD/EFTR (depending on recurrence characteristics, namely depending on adequate elevation of the lesion) instead of avulsion methods, in order to allow complete resection of that area and also histological diagnosis (Fig. 5).

**FU and Prognosis**
According to ENETS, completely resected tumors with <1 cm, G1–G2 grading, with no MP invasion or LNM, do not require regular FU [18, 24]. Additional FU for other tumors is presented in Table 3.

R-NETs have the best overall survival of all GI-NETs largely due to the high incidence of small lesions without evidence of invasion. Tumor stage at diagnosis is the most important prognostic factor. Localized T1 r-NETs have a 5-year survival of 98–100%, while those with regional and distant metastases have a 54–74 and 15–37% survival, respectively [23].

**Conclusion**
GI-NETs are increasing in incidence, in part due to expanding indications for endoscopy, so endoscopists need to be aware of specific characteristics regarding diagnosis, staging, and management. ER is a cornerstone of the management of these tumors, and the endoscopist should be familiarized with different technique modalities in order to maximize resection rates and long-term outcomes. Also, we would like to point out that multidisciplinary collaborations are essential for the diagnosis and management of these tumors and that prospective institutional and national registries and consortiums would allow research progress for the optimal management of NETs in the future.

**Statement of Ethics**
Due to the nature of the article (review article) ethical approval was not required.

**Conflicts of Interest Statement**
The authors have no conflicts of interest to declare.
No subsidies or grants supported this work.

The 4 authors contributed equally to the planning and organization of the article. J.C. was in charge of bibliographic research and first draft. D.L., P.P.N. and M.D.R. contributed to the improvement of the final draft and overall critical review.

References

1. Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. *Clin Med Insights Endocrinol Diabetes*. 2019 Oct;12:11795514984058.
2. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. *Endocr Relat Cancer*. 2010 Oct;17(4):909–18.
3. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcome in patients with neuroendocrine tumors in the United States. *JAMA Oncol*. 2017 Jan;76(2):182–8.
4. Nagepaaal IA, Odze RD, Klimstra D, Paradis A, Rindi G, Kos-Kudla B, Knigge U, et al.; Barcelone Consensus Conference participants. ENETS consensus guidelines for the management and treatment of neuroendocrine tumors: diagnosis, treatment and follow-up. *Ann Oncol*. 2018 Oct;23 Suppl 7:vii124–30.
5. Öberg K, Knigge U, Kwekkeboom D, Perren VS, Rugge M, Schirmacher P, et al.; WHO Classiﬁcation of Tumours Editorial Board. The 2019 WHO classiﬁcation of tumours of the digestive system. *Histopathology*. 2020 Jan;76(2):182–8.
6. Öberg K, Knige U, Kwekkeboom D, Perren VS; ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii124–30.
7. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knige U, et al.; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastrointestinal neuroendocrine neoplasms. *Neuroendocrinology*. 2012;95(2):74–87.
8. Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. *World J Gastrointest Endosc*. 2015 Apr,7(4):346–53.
9. Basuroy R, Srirajaskanthan R, Prchalhasias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. *Aliment Pharmacol Ther*. 2014 May;39(10):1071–84.
10. Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Neuroendocrine tumours of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? *Endoscopy*. 2010 Aug;42(8):664–71.
11. Chin JL, O’Toole D. Diagnosis and management of upper gastrointestinal neuroendocrine tumors. *Clin Endosc*. 2017 Nov;50(6):520–9.
12. Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. *Br J Surg*. 2018 Oct;105(11):1480–6.
13. Scherübl H, Cadiot G. Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance. *Vic Med*. 2017 Oct;33(5):332–8.
14. Lahner E, Esposito G, Angeletti S, Corleto VD, Pilozzi E, Di Giulio E, et al. Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging: a case series in a referral center. *Eur J Gastroenterol Hepatol*. 2016 Apr;28(4):463–8.
15. Zilli A, Arcidiacono PG, Conte D, Massironi M. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. *Dig Liver Dis*. 2018 Jan;50(1):6–14.
16. Kunz PL, Reidy-lagunes D, Anthony ÞL, Bertero EM, Brendtro K, Chan JA, et al. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumours. *Pancreas*. 2013;42(4):557–77.
17. Hope TA, Bergland EB, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumours. *J Nucl Med*. 2018 Jan;59(1):66–74.
18. Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for gastroenteroendocrine neuroendocrine neoplasms. *Neuroendocrinology*. 2016;103(2):119–24.
19. Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? *World J Gastroenterol*. 2013 Dec;19(46):8687–95.
20. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. *Gastroenterol Res Pract*. 2014;2014:253860.
21. Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GN. Endoscopic outcome of endoscopic and surgical resection for foregut neuroendocrine tumors. *J Dig Dis*. 2015 Oct;16(10):595–600.
22. Uygun A, Kadıyafıçlı A, Polat Z, Yilmaz K, Gunał A, Demir H, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. *J Surg Oncol*. 2014 Feb;109(2):71–4.
23. Basuroy R, Haji A, Ramage JK, Quaglia A, Sri-rajaskanthan R. Review article: the investigation and management of rectal neuroendocrine tumours. *Aliment Pharmacol Ther*. 2016 Aug;44(4):332–45.
24. Knige U, Capdevila J, Bartsch DK, Budin E, Falkery J, Kianmanesh R, et al.; Antibes Consensus Conference Participants; Antibes Consensus Conference Participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. *Neuroendocrinology*. 2017;105(3):310–9.
25. Kwon YH, Jeon SW, Kim GH, Kim JI, Chung IK, Jee SR, et al. Long-term follow-up of endoscopic resection for type 3 gastric NET. *World J Gastroenterol*. 2013 Dec;19(46):8703–8.
26. Evans JA, Chandrasekharaya V, Chathaki KV, Decker GA, Early DS, Fisher DA, et al.; ASGE Standards of Practice Committee. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc*. 2015 Jul;82(1):1–8.
27. Yao IC, Hassan M, Phan A, Dogahoy C, Leary C, Mares JE, et al. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. *J Clin Oncol*. 2013;26(18):3063–72.
28. Lyu KD, Kidd M. A 5-Decade Analysis of 13,715 Carcinoid Tumors. *Cancer*. 2003 Feb 15;97(4):934–59.
29. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. *Best Pract Res Clin Gastroenterol*. 2005;19:679–97.
30. Randle RW, Ahmed S, Newman NA, Clark CJ. Clinical Outcomes for Neuroendocrine Tumors of the Duodenum and Ampulla of Vater: A Population-Based Study. *J Gastrointest Surg*. 2014 Feb;18(2):354–62.
31. Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Cho GS, et al. Long-term outcome of endoscopic and surgical resection for type I gastric neuroendocrine tumors. *J Gastroenterol*. 2016 Aug;42(3):6817–28.
32. Gincul R, Ponchon T, Napoleon B, Scoazec JY, Guillaud O, Saurin JC, et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. *Endoscopy*. 2016 Nov;48(11):979–86.
33 Kim GH, Kim JJ, Jeong SW, Moon JS, Chung IK, Jee SR, et al.; Korean College of Helicobacter and Upper Gastrointestinal Research. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J Gastroenterol Hepatol. 2014 Feb;29(2):318–24.
34 Matsumoto S, Miyatani H, Yoshida Y, Nokubi M. Duodenal carcinoid tumors: 5 cases treated by endoscopic submucosal dissection. Gastrointest Endosc. 2015 May;81(5):1272–3.
35 Suzuki S, Ishii N, Uemura M, Deshpande GA, Matsuda M, Iizuka Y, et al. Endoscopic submucosal dissection (ESD) for gastrointestinal carcinoid tumors. Surg Endosc. 2012 Mar; 26(3):759–63.
36 Curcio G, Granata D, Ligresti A, Barresi L, Liotta R, et al. Underwater submucosal resection of a carcinoid tumor of the duodenal bulb. Gastrointest Endosc. 2010 Jun; 61(6):1057–61.
37 Cortez-Pinto J, Mão De Ferro S, Claro I, Claves P, Dias Pereira A. Duodenal Neuroendocrine Tumor Resection with a New Duodenal Full-Thickness Resection Device. GE Port J Gastroenterol. 2020 Jul;27(4): 290-292.
38 Neumann H, Ramesh J, Wilcox CM, Mönkemüller K. Resection of carcinoids in the duodenal bulb using the band ligation technique with the Duette mucosectomy device. Endoscopy. 2013;45(S 02 Suppl 2 UCTN):E365–6.
39 Otaki Y, Homma K, Nawata Y, Imazumi K, Arai S. Endoscopic mucosal resection with circumferential mucosal incision of duodenal carcinoid tumors. World J Gastrointest Endosc. 2013 Apr;5(4):197–200.
40 Khara HS, Shovlin GJ, Johal AS, Diehl DL. Endoscopic banding without resection (BWR) technique for treatment of diminutive neuroendocrine tumors in the duodenum. Endosc Int Open. 2019 Feb;7(2):E302–7.
41 Nassri AB, Alkhasawneh A, Scolapio JS, Malespin MH, Ribeiro BS. Safety and efficacy of over-the-scope clip-assisted full thickness resection of duodenal subepithelial tumors: A case report. World J Gastrointest Endosc. 2019 Feb;11(2):168–73.
42 Massironi S, Kampf B, Partelli S, Panzuto F, Rossi RE, Faggiano A, et al. Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Ann Surg Oncol. 2018 Oct;25(11):3200–6.
43 Ito T, Sasano H, Tanaka M, Osauma RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010 Feb;45(2):234–43.
44 Caplin M, Sundin A, Nilsson O, Baum RP, Klose KJ, Kelestimur F, et al.; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95(2):88–97.
45 Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.
46 Gleeson FC, Levy MJ, Dozois EJ, Larson DW, Wong Kee Song LM, Boardman LA. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endosc. 2014 Jul;80(1):144–51.
47 Shim KN, Yang SK, Myung SJ, Chang HS, Jung SA, Choe JW, et al. Atypical endoscopic features of rectal carcinoids. Endoscopy. 2004 Apr;36(4):313–6.
48 Lin CK, Chung CS, Huang WC. Rectal carcinoid tumour observed by magnifying colonoscopy with narrow band imaging. Dig Liver Dis. 2014 Jul;46(7):e27.
49 Ishii N, Horiki N, Itoh T, Maruyama M, Matsuda M, Setoyama T, et al. Endoscopic submucosal dissection and preoperative assessment with endoscopic ultrasonography for the treatment of rectal carcinoid tumors. Surg Endosc. 2010 Jun;24(6):1413–9.
50 Fine C, Roquin G, Terrebonne E, Lecomte T, Coriat R, Do Dao C, et al. Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE). United European Gastroenterol J. 2019 Oct;7(8):1102–12.
51 Yang DH, Park Y, Park SH, Kim KJ, Ye BD, Byeon JS, et al. Cap-assisted EMR for rectal neuroendocrine tumors: comparisons with conventional EMR and endoscopic submucosal dissection (with videos). Gastrointest Endosc. 2016 May;83(5):1015–22.
52 Choi CW, Kang DH, Kim HW, Park SB, Jo WS, Song GA, et al. Comparison of endoscopic resection therapies for rectal carcinoid tumor: endoscopic submucosal dissection versus endoscopic mucosal resection using band ligation. J Clin Gastroenterol. 2013 May-Jun;47(5):432–6.
53 Chen T, Yao LQ, Xu MD, Zhang YQ, Chen WF, Shi Q, et al. Efficacy and Safety of Endoscopic Submucosal Dissection for Colorectal Carcinoids. Clin Gastroenterol Hepatol. 2016 Apr;14(4):575–81.
54 Jeon SM, Lee JH, Hong SP, Kim TI, Kim WH, Cheon JH. Feasibility of salvage endoscopic mucosal resection by using a cap for remnant rectal carcinoids after primary EMR. Gastrointest Endosc. 2011 May;73(5):1009–14.
55 Hurlstone DP, Shorthouse AJ, Brown SR, Tiffin N, Cross SS. Salvage endoscopic submucosal dissection for residual or local recurrent intraepithelial neoplasia in the colorectum: a prospective analysis. Colorectal Dis. 2008 Nov;10(9):891-7.
56 Cha JH, Jung DH, Kim J, Youn YH, Park H, Park JJ, et al. Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors. Sci Rep. 2019 Mar 20;9(1):4911.
57 Meier B, Albrecht H, Wiedbrauck T, Schmidt A, Caca K. Full-thickness resection of neuroendocrine tumors in the rectum. Endoscopy. 2020 Jan;52(1):68–72.